If you find yourself in a situation where you can no longer independently easily carry out the daily necessities of life, it is because of old age or a
Location: United States, Missouri, California
Employees: 11-50
Total raised: $20M
Investors 1
| Date | Name | Website |
| - | Alloy Vent... | alloyventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.09.2008 | - | $20M | - |
Mentions in press and media 10
| Date | Title | Description |
| 06.04.2017 | Adaptimmune raises $106M for pipeline work; KaloBios chief says biotech is on track for Chagas drug filing | Cameron Durrant → Matrix Capital Management has scooped up $42 million worth of Adaptimmune stock $ADAP, paying a slight premium for the block of shares. “We are delighted to welcome Matrix to our shareholder base through... |
| 11.04.2016 | KaloBios distancing itself from Martin Shkreli with new drug pricing model | Everything at KaloBios, says Durrant, will be “180 degrees different from what has gone before.” Shkreli’s hep C style pricing plan for the Chagas treatment? Gone for good.It’s up to the company, he says, “to lead by example. Pricing is a c... |
| 13.11.2015 | Monoclonal antibody player KaloBios shutting down | Stock has progressively crashed, with a series of notable setbacks – such as Sanofi walking away from its antibacterial program in the midst of a Phase 2 study, even after a $35 million investment in the company. Sanofi never said what caus... |
| 30.10.2013 | Which venture capital firm’s healthcare investment picks secured the most IPOs? | I won’t get into Aratana Therapeutics (Nasdaq: PETX) because the biopharmaceutical company develops treatments for animals. Acceleron Pharma: (Nasdaq: XLRN) raised $96.7 million after it priced at the high end of its share price range. The ... |
| 23.09.2008 | Engineered antibody maker KaloBios takes on $20M for clinical trials | South San Francisco, Calif.-based KaloBios Pharmaceuticals, which develops non-human antibodies for use in human bodies, has taken $20 million in its fourth round of venture funding. KaloBios is currently going through seven first- and seco... |
| 24.07.2007 | KaloBios draws in $20M for antibody drugs | KaloBios, a Palo Alto, Calif., biotech antibody-therapeutic company, raised $20 million in a third funding round. The company is developing new drugs based on monoclonal antibodies, which target specific cells or proteins in the body. Its l... |
| 13.10.2006 | Pharmaceuticals co., KaloBios, announces search for $40M | KaloBios, a Palo Alto company developing treatments for pseudomonas lung infections and autoimmune diseases including rheumatoid arthritis, is looking to raise up to $40 million in a third round of funding. Newly-appointed KaloBios chief ex... |
| - | Which venture capital firm’s healthcare investment picks secured the most IPOs? | Biotechnology and healthcare companies have been going public at a good clip this year, at a rate that overshadows the past few years. But initial public offerings are not what they used to be. Although they used to mark an exit for a compa... |
| - | KaloBios distancing itself from Martin Shkreli with new drug pricing model | KaloBios, the drug company that was at death’s door until Turing Pharmaceuticals snapped it up under direction from Martin Shkreli, is making moves to distance itself from its notorious former CEO. Monoclonal antibody player KaloBios was in... |
| - | Monoclonal antibody player KaloBios shutting down | KaloBios, a once-promising monoclonal antibody player, just announced it is winding down operations. The San Francisco company, which laid off 17 employees – about 61 percent of its workforce – just last week, was exploring “strategic alter... |